Products
Pre-made Apamistamab benchmark antibody ( Whole mAb Radiolabelled, anti-PTPRC therapeutic antibody, Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-029
Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. ... It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-029-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-029-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-029-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-029-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody |
| INN Name | Apamistamab |
| Target | PTPRC |
| Format | Whole mAb Radiolabelled |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Discontinued | Hodgkin's disease;Non-Hodgkin's lymphoma |
| Development Tech | na |
